Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content. Terms and conditions, including restrictions on redistribution, apply. Copyright © 1996-2009 PR Newswire Association LLC. All Rights Reserved. A United Business Media company.